Science
Oncolytic immunotherapy is the next frontier in cancer treatment uniquely designed to engage the immune system. Oncolytic immunotherapy refers to a versatile biological platform that allows for the insertion of transgenes expressing proteins that can enhance oncolytic activity to induce the destruction of local cancer cells and immune responses to potentially generate systemic anti-tumor effects. Oncolytic immunotherapies may be used with other therapies as well, and may possibly enhance anti-tumor activity.
Igniting a systemic immune response to cancer
Replimune’s approach aims to destroy tumors locally and ignite a systemic anti-tumor response with the goal to improve outcomes for patients with cancer.
Learn how oncolytic immunotherapy and the RPx platform work
RPX Platform
RPX is a next-generation HSV-1–based oncolytic immunotherapy platform, with a dual mechanism of action involving the direct destruction of tumor cells and induction of a systemic anti-tumor immune response with enhanced T-cell activation and replication in tumor cells.
RPx can be injected into most lesions, including both superficial and deep lesions, which provides the opportunity to target tumor and immune microenvironments to address tumor heterogeneity that can contribute to mechanisms of immune checkpoint inhibitor resistance.
Explore our Clinical Trials
Clinical trials allow us to carefully test and collect data about our investigational oncolytic immunotherapies before they can be approved for use. Learn more about our clinical trials or find a relevant one near you.